Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 193.76 USD 0.1% Market Closed
Market Cap: 55.5B USD

Intrinsic Value

The intrinsic value of one BDX stock under the Base Case scenario is 273.52 USD. Compared to the current market price of 193.76 USD, Becton Dickinson and Co is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BDX Intrinsic Value
273.52 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Becton Dickinson and Co

What is Valuation History?
Ask AI Assistant
What other research platforms think about BDX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BDX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Becton Dickinson and Co.

Explain Valuation
Compare BDX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Heavy reliance on higher-margin hospital consumables leaves BD vulnerable to increasing cost pressures and potential manufacturing capacity constraints, which could compress margins if supply chain challenges persist.

The company’s sizable M&A-driven growth strategy, highlighted by its acquisition of C. R. Bard, may lead to integration challenges and divert management’s focus away from organic product innovation, dampening long-term competitiveness.

Growing regulatory scrutiny over infection-prevention protocols and device safety could lead to higher compliance costs and longer product approval timelines, particularly for BD’s advanced infusion and surgical solutions.

Bull Theses

BD’s entrenched leadership in core medical device categories, including syringes and infusion systems, provides stable demand and strong pricing power in an essential, non-discretionary market.

Its significant R&D investments in advanced diagnostic tools and biosafety solutions position BD to capture emerging growth opportunities, especially as healthcare systems increasingly value infection prevention technologies.

A broad global footprint and established distribution networks protect BD against regional shocks, while continued expansion in emerging markets offers both long-term volume growth and the chance to deepen customer relationships.

Show More Less
How do you feel about BDX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Becton Dickinson and Co

Current Assets 9.3B
Cash & Short-Term Investments 649m
Receivables 3B
Other Current Assets 5.6B
Non-Current Assets 46.1B
PP&E 7B
Intangibles 36B
Other Non-Current Assets 3.1B
Current Liabilities 8.3B
Other Current Liabilities 8.3B
Non-Current Liabilities 21.6B
Long-Term Debt 17.6B
Other Non-Current Liabilities 4B
Efficiency

Free Cash Flow Analysis
Becton Dickinson and Co

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Becton Dickinson and Co

Revenue
21.8B USD
Cost of Revenue
-11.9B USD
Gross Profit
9.9B USD
Operating Expenses
-6.9B USD
Operating Income
3B USD
Other Expenses
-1.3B USD
Net Income
1.7B USD
Fundamental Scores

BDX Profitability Score
Profitability Due Diligence

Becton Dickinson and Co's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Healthy Operating Margin
Sustainable 3Y Average Operating Margin
49/100
Profitability
Score

Becton Dickinson and Co's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

BDX Solvency Score
Solvency Due Diligence

Becton Dickinson and Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
45/100
Solvency
Score

Becton Dickinson and Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BDX Price Targets Summary
Becton Dickinson and Co

Wall Street analysts forecast BDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BDX is 209.55 USD with a low forecast of 184.83 USD and a high forecast of 295.58 USD.

Lowest
Price Target
184.83 USD
5% Downside
Average
Price Target
209.55 USD
8% Upside
Highest
Price Target
295.58 USD
53% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Dec 5, 2025
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for BDX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BDX Insider Trading
Buy and sell transactions by insiders

BDX News

Other Videos
What is the Intrinsic Value of one BDX stock?

The intrinsic value of one BDX stock under the Base Case scenario is 273.52 USD.

Is BDX stock undervalued or overvalued?

Compared to the current market price of 193.76 USD, Becton Dickinson and Co is Undervalued by 29%.

Back to Top